HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the second quarter ended June 30, 2014.
SECOND QUARTER 2014 OPERATIONAL AND FINANCIAL HIGHLIGHTS
Recent Operational Highlights
* The final patient of cohort six is currently being treated in the Phase I clinical trial evaluating Bio-Path’s lead product candidate, BP-100-1.01 (Liposomal Grb-2) in blood cancers. Assuming this patient successfully completes the treatment cycle, we anticipate concluding the sixth cohort of the study by the end of the third quarter.
Help employers find you! Check out all the jobs and post your resume.
